THE BUSINESS OF LONGEVITY – Chapter EightThe Investor Pitch

What Exactly Are Investors Being Asked to Believe?

At some point, almost every emerging biotechnology company faces the same challenge.

Science costs money.

Research costs money.

Laboratories cost money.

Clinical expansion costs money.

And eventually, someone has to finance it.

That is where investors enter the story.

Throughout this investigation, I have examined Wellbeing International Foundation from several different perspectives.

First as a healthcare organisation.

Then through its scientific research.

Then through its leadership, corporate history, structure and ownership.

But there is another audience we have not yet examined closely.

The investors.

Wellbeing has publicly confirmed that it has raised private investment.

That immediately creates an important new question.

What exactly are investors investing in?

From Patient to Investor

Patients and investors approach Wellbeing from completely different directions.

A patient considering Cell-Free Therapy wants to know:

Does it work?

Is it safe?

What evidence supports it?

An investor asks something entirely different.

How big could this become?

How many patients could be treated?

How many clinics could operate?

What intellectual property exists?

What margins could be achieved?

What might the company eventually be worth?

Those questions transform the conversation.

A treatment becomes a product.

A scientific programme becomes intellectual property.

A patient becomes revenue.

And future medical potential becomes future company value.

That transformation is not sinister.

It is how biotechnology businesses are built.

But it means scientific claims can suddenly acquire financial significance.

The 2026 Funding Round

Wellbeing announced that it had successfully closed the first tranche of its 2026 investment round.

The company's public announcement describes the fundraising as supporting continued development, research, operational capacity and expansion.

That tells us something about the company's ambitions.

But comparatively little about the investment itself.

Publicly, we still do not know:

• how much was raised;

• what valuation investors accepted;

• what percentage of the business was offered;

• what type of securities investors received;

• who participated;

• what financial projections were provided;

• what exit strategy was presented;

• what risks were disclosed.

For a private company, confidentiality surrounding these matters can be entirely normal.

But it creates a significant limitation for an outside investigation.

We know an investment proposition exists.

We do not yet have the complete proposition.

What Are Investors Buying?

This may be the most fundamental question of all.

When someone invests in Wellbeing, what exactly do they acquire?

Shares in the operating company?

Shares in a holding company?

Convertible debt?

Preference shares?

An interest in intellectual property?

Another financial instrument?

Without the investment documentation, we should not speculate.

But the distinction matters enormously.

An investor can believe passionately in a company's technology while owning shares in an entity that does not directly own that technology.

That is why professional due diligence examines not simply the brand but the legal structure beneath it.

The Importance of the Science

This is where the scientific investigation becomes financially relevant.

Wellbeing now has something it did not previously possess.

A peer-reviewed scientific publication.

As established earlier in this series, the paper is genuine.

The journal is genuine.

The research produced interesting findings.

But the study also has substantial limitations.

Only fourteen participants completed the programme.

There was no placebo group.

There was no untreated control group.

Participants underwent numerous interventions simultaneously.

Researchers commercially connected to the programme conducted the study.

The authors themselves acknowledged the need for larger controlled trials.

Scientifically, that makes the publication preliminary.

Commercially, however, the words peer reviewed can carry enormous value.

When Scientific Credibility Becomes Commercial Value

Imagine two investment propositions.

The first says:

We have developed an experimental longevity programme.

The second says:

Our longevity programme has been published in a peer-reviewed scientific journal.

Both statements might be true.

But psychologically, they communicate very different levels of credibility.

That is why the exact language used in investor materials matters.

Does the investment proposition describe the research as preliminary?

Does it explain the absence of a control group?

Does it disclose the small participant population?

Does it explain that several interventions were delivered simultaneously?

Or does the phrase "peer reviewed" become shorthand for something much stronger?

Until the private investor materials are available, I cannot answer those questions.

But they are questions worth asking.

The Difference Between Published and Proven

This distinction sits at the heart of the entire investigation.

Published does not mean proven.

Peer review means researchers have submitted work that has undergone scholarly assessment and been accepted for publication.

It does not automatically establish that a commercial treatment is clinically effective.

That normally requires a much larger body of evidence.

Independent replication.

Controlled trials.

Larger populations.

Longer follow-up.

Clear clinical endpoints.

For investors unfamiliar with clinical research, those distinctions may not always be obvious.

That makes accurate presentation particularly important.

The Longevity Opportunity

There is another reason this matters.

Longevity is becoming an extremely attractive investment narrative.

The world's population is ageing.

Wealthy consumers increasingly spend money attempting to extend healthspan.

Biotechnology companies are exploring cellular ageing, epigenetics, senescence, gene therapy and regenerative medicine.

Investors understandably want exposure to what could become an enormous future industry.

That creates opportunity.

It also creates conditions in which expectations can move faster than evidence.

Whenever those two things happen simultaneously, due diligence becomes essential.

Selling the Future

Investment is fundamentally about the future.

Investors rarely buy companies solely because of what they are worth today.

They invest because of what they believe those companies could become tomorrow.

That requires projections.

More clinics.

More patients.

More territories.

More research.

More treatments.

More revenue.

Perhaps eventually an acquisition, flotation or another form of exit.

There is nothing unusual about any of that.

But the further an investment valuation depends upon future events, the more important the assumptions behind those projections become.

What Would Change This Investigation

There are several documents that could dramatically advance this investigation.

The investor presentation.

The information memorandum.

The term sheet.

The subscription agreement.

Financial forecasts.

The capitalisation table.

Shareholder agreements.

Risk disclosures.

These documents would allow a much more important comparison than anything possible from public announcements alone.

What does Wellbeing tell patients?

What does Wellbeing tell scientists?

And what does Wellbeing tell investors?

If those three narratives align, that would significantly strengthen the company's position.

If they differ materially, understanding why would become an important matter of public interest.

The Questions I Would Ask Before Investing

If I were considering this investment myself, my questions would be straightforward.

What is the current company valuation?

How was that valuation calculated?

How much revenue currently comes from patients?

Is the company profitable?

How much additional capital will be required?

Who owns the core intellectual property?

Which legal entity am I investing in?

What percentage of that entity will I own?

What clinical evidence supports the commercial projections?

What regulatory approvals could be required as the business expands?

What happens if larger clinical trials fail to reproduce the pilot results?

And ultimately:

How do I get my money back?

These are not hostile questions.

They are the questions any serious investor should ask.

Science Risk Becomes Investment Risk

There is another important connection that prospective investors should understand.

If part of the value of a biotechnology company depends upon its science, weaknesses in that science become financial risks.

Imagine that future independent trials fail to reproduce the preliminary findings.

What happens to the valuation?

What happens if regulators take a different position on the therapy?

What happens if manufacturing requirements change?

What happens if intellectual-property protection proves weaker than expected?

Scientific uncertainty does not disappear when investment arrives.

It becomes part of the investment risk.

What We Can—and Cannot—Conclude

At this stage, there is no evidence available to me demonstrating that Wellbeing has misled investors.

That needs to be stated clearly.

We have not seen the private investment materials.

We therefore cannot responsibly claim to know what representations were made to prospective investors.

What we can establish is that Wellbeing is raising private capital while developing and commercialising a longevity programme whose published clinical evidence remains preliminary.

That combination makes the investor materials extremely important.

The Question Has Changed Again

When this investigation began, I asked:

Does the treatment work?

Then:

What does the scientific paper actually prove?

Then:

Who runs the organisation?

Then:

Who owns it?

Now the question becomes:

What future are investors being asked to finance?

Because there is an enormous difference between investing in established medicine and investing in the possibility that emerging science might eventually become established medicine.

Both can be legitimate investments.

But they carry completely different risks.

Looking Ahead

There is now one more connection that deserves investigation.

The money behind the company is only one side of the equation.

The other is the money coming from patients.

Wellbeing has acknowledged patient revenue as part of its historical funding model.

That raises a fascinating question about the economics of the business.

How does a longevity programme move from laboratory concept to a treatment carrying a substantial price?

What exactly is the patient paying for?

Where is the treatment delivered?

Who provides it?

And how much of the organisation's growth has effectively been financed by the people receiving the programme?

That is where this investigation goes next.

Chapter Nine: The £37,000 Question

Following the Patient Money Behind Cell-Free Therapy

Because when an experimental medical programme becomes both a treatment and an investment proposition, understanding who pays—and where that money goes—becomes impossible to ignore.